Asthma
Conditions
Interventions
In addition to asthma controller medications at the time of enrollment, carbocisteine 500 mg x 3/day (after meals) was added.
Asthma controller medications at the time of enrollment was continued.
Sponsors
Dokkyo Medical University, Department of Pulmonary Medicine and Clinical Immunology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients diagnosed with mild to moderate persistent asthma based on the "Classification of Asthma Severity in View of Current Treatment (in adult)" in the 2006 Asthma Prevention and Management Guideline (Japan )
Exclusion criteria
Exclusion criteria: 1) patients intolerant to carbocisteine; 2) patients planned to take oral steroids, antibacterials/antibiotics, antitussives, or expectorants at the start of the study; 3) patients participating in another study at the start of the study; 4) patients who had started hyposensitization therapy or nonspecific therapy within 3 months or who planned on such therapy after the start of the study; 5) patients with comorbidities such as COPD or bronchiectasis; 6) patients with serious hepatic disease, renal disorders, heart disease, or other comorbidities; 7) patients with malignant tumors; 8) patients who were or may have been pregnant; 9) lactating patients; 10) patients determined unsuitable by an investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of the common cold | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Frequency of acute exacerbation 2. Cumulative percentage of patients with first acute exacerbation 3. Peak expiratory flow [PEF] rate upon morning and evening 4. Pulmonary function (forced vital capacity [FVC], forced expiratory volume [FEV] 1.0, FEV 1.0%, and % FEV 1.0 ) | — |
Countries
Japan
Contacts
Public ContactRitsuko Kondo
WILL Medical Communications Inc. Editorial Dept
Outcome results
None listed